Eyeworld

FALL 2026 | EYEWORLD | 57 R REWIND. REFRESH. REFINE. About the physicians Priya Mathews, MD, MPH Assistant Medical Director Director of Cornea and Ocular Surface Disease Center for Sight Sarasota, Florida George O. Waring IV, MD Waring Vision Institute Mt. Pleasant, South Carolina Robert Weinstock, MD Medical Director Eye Institute of West Florida Regional Medical Director EyeCare Partners Largo, Florida F irst-generation presbyopia-correcting IOLs established categories based on range of vision. Since then, there have been several iterations and additions within these categories, refining vision profiles, improving quality of vision, and reduc- ing unwanted side effects. When it comes to true presbyopia-correct- ing lenses, there are two main categories, which have been recently described by the ESCRS and ASCRS Functional Vision Working Groups based on what its members think best fits and standardizes academic discussion of these IOLs: extended depth of field and full depth of field. Both of these categories have new additions (at least new to the U.S. market), and physicians with experience are excited about the results. The new kid: full depth of field George O. Waring IV, MD, implanted the first FDA-approved FineVision HP IOL (BVI Medical) in the U.S. This lens, Dr. Waring said, has a long history in Europe, being the first trifocal IOL worldwide designed by Damien Gatinel, MD, PhD. "This lens has enjoyed very productive uti- lization globally. We were excited and relieved to receive FDA approval earlier this year," Dr. Waring said. The lens has some attributes making it unique in the U.S. market, Dr. Waring said. It utilizes a combination of two optical tech- nologies, apodization and convolution. "This combination of optical features harmonizes light energy and reduces side effects," Dr. Waring said. He also mentioned that it has a four-foot- plate haptic design that allows for auto-centra- tion, which he said could improve effective lens position and make refractive drift less likely. Once a toric version is available in the U.S., Dr. Waring said the haptic design will be helpful for rotational stability. Robert Weinstock, MD, also hailed the stability of the four-point fixation of the double C-loop haptic design. "It unfolds quickly and centers beautifully inside the capsular bag. This is a huge value feature especially in a multifo- cal where IOL centration on the visual axis is critical. I find that conventional C-loop design IOLs tend to decenter more easily and often tilt or shift position slightly as the capsule heals and contracts around it. The design of the FineVision IOL is more stable," Dr. Weinstock said. He also said the FineVision HP has a "very regular pattern to its diffractive steps with a smooth transition between steps," to which he credits the lens' quality of vision with minimal dysphotopsias. What sets the FineVision HP apart for Priya Mathews, MD, is its quality of distance vision and level of near vision. "It achieves better read- ing than most multifocals that I have experience with, so that's been nice for those patients who value not having to wear glasses as much as possible, even for fine print," she said. New in extended depth of field In the extended depth of field category, the newcomer is TECNIS PureSee (Johnson & Johnson Vision), which received FDA approval in March 2026. This lens, Dr. Waring said, has a novel optical approach. "It's the first truly non-diffractive range of field lens available by using a continuous power change on the posterior surface of the IOL, which elongates by Liz Hillman Editorial Co-Director Presbyopia-correcting IOLs: the new kids on the block Dr. Waring implants the first FDA-approved FineVision HP trifocal IOL in the U.S. Source: George O. Waring IV, MD continued on page 58

• Cover